CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 39 enrolled
Drug / intervention
QNASL +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01852513
NCT01852513Phase 4Completed
CompareCT.gov

Allergic Rhinitis Changes the Sinus Microbiome

University of Chicago·interventional·Posted May 13, 2013·Updated Oct 9, 2020

In Brief

A Phase 4 clinical trial evaluating QNASL and Placebo nasal spray for Seasonal Allergic Rhinitis. Completed, enrolled 39 participants across 1 site.

Detailed Summary

The investigators hypothesize that treatment with QNASL will reduce nasal mucosal inflammation induced by the allergy season and prevent the changes in the microbiome caused by the allergy season.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 13, 2013
Enrollment StartJan 1, 2013
Primary CompletionNov 1, 2013
Study CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 13.1 years ago

Interventions

QNASLdrug

Placebo nasal spraydrug